Surface Oncology Inc

+0.55 (+7.47%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)367.32M
Current PE17.32
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.64 Million
Adjusted EPS-$0.32
See more estimates
10-Day MA$7.57
50-Day MA$7.81
200-Day MA$8.36
See more pivots

Surface Oncology Inc Stock, NASDAQ:SURF

50 Hampshire Street, 8th floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.714.4096
Number of Employees: 51


Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firmâ??s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.